Tweet
<img alt="" height="1" width="1" />
Pfizer's Sutent fails in lung cancer study
BusinessWeek
Drug developer Pfizer Inc. said Monday its drug Sutent failed a late-stage study focusing on lung cancer patients. The company said Sutent, also called sunitinib, failed to meet its goal of improving overall survival rates in patients who had ...
Pfizer:Cancer Pill Sutent Fails Endpoint In Lung-Cancer TrialWall Street Journal
Pfizer's Sutent meets lung cancer trial's 2nd goalReuters
Topline Results From Phase 3 Trial of Sunitinib With Erlotinib in Advanced Non ...PR Newswire (press release)
all 32 news articles »
More...